Extract of a polyherbal formulation ameliorates experimental nonalcoholic steatohepatitis

10.1016/j.jtcme.2014.12.002

Mohammed Azeemuddin；Mohamed Rafiq；Suryakanth Dattatraya Anturlikar；Lakkavalli Mohan Sharath Kumar；Pralhad Sadashiv Patki；Uddagiri Venkanna Babu；Ramakrishnan Shyam

antifibrotic ； high-fat diet ； insulin resistance ； Liv.52 ； nonalcoholic steatohepatitis

Journal of Traditional and Complementary Medicine

6卷2期（2016 / 04 / 01）

160 - 167

英文

The objective of the present study is to evaluate the effect of the extract of a well-known hepatospecific polyherbal formulation, Liv.52, in an experimental model of high-fat diet (HFD)-induced nonalcoholic steatohepatitis (NASH) in rats. Feeding a HFD for 15 weeks resulted in significant impairment of the lipid profile, elevation of hepatic enzyme markers, and insulin resistance in rats. The histological examination of the liver furthermore indicated fibrotic changes and fat deposition in hepatic tissues. The treatment with Liv.52 extract [125 mg/kg body weight per os (b.wt. p.o.)], which was administered from week 9 onward, reversed the HFD-induced changes to a statistically significant extent, compared to the untreated positive control animals. The effect observed with Liv.52 extract was comparable to that of pioglitazone (4 mg/kg b.wt.), a standard drug that is useful in the management of NASH. The treatment with Liv.52 extract significantly reduced steatosis, collagen deposition, and necrosis in hepatic tissues, which indicates its antifibrotic and antinecrotic properties. The results obtained in the present set of experiments indicate that Liv.52 extract effectively reverses metabolic and histological changes associated with HFD-induced NASH.

1. Adachi, M,Ishii, H.(2002).Role of mitochondria in alcoholic liver injury.Free Radic Biol Med,32,487-491.
2. Aguilar, FP,Benlloch, S,Berengnes, M,Beltram, B,Berengner, J(2004).Nonalcoholic steatohepatitis: physiopathological, clinical and therapeutic implications.Rev Esp Enferm Dig,96,628-648.
3. Aithal, GP,Thomas, JA,Kaye, PV(2008).mized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.Gastroenterology,135,1176-1184.
4. Altunkaynak, BZ(2005).Effects of high fat diet induced obesity on female rat livers (a histochemical study).Eur J Gen Med.,2,100-109.
5. Ballinger, SW(2005).Mitochondrial dysfunction in cardiovascular disease.Free Radic Biol Med,28,1278-1295.
6. Chauhan, BL,Kulkarni, RD(1991).Effect of liv52, a herbal preparation, on absorption and metabolism of ethanol in humans.Eur J Clin Pharmacol,40,189-191.
7. Chauhan, BL,Kulkarni, RD(1990).Dose response of ethanol after chronic administration of alcohol and effect of Liv.52 on blood, liver ethanol and acetaldehyde levels in rats.Eur J Pharmacol,5,1864.
8. Chen, CC,Liu, IM,Cheng, JT(2006).Improvement of insulin resistance by miracle fruit (Synsepalum dulcificum) in fructose-rich chow-fed rats.Phytother Res,20,987-992.
9. Chitturi, S,Farrell, GC(2001).Etiopathogenesis of nonalcoholic steatohepatitis.Semin Liver Dis,21,27-41.
10. Dai, DL,Shen, W,Yu, HF,Guan, XQ,Yi, YF(2006).Effect of Cordyceps sinensis on uncoupling protein 2 in experimental rats with nonalcoholic fatty liver.J Health Sci.,52,390-396.
11. Day, CP(2002).Pathogenesis of steatohepatitis.Best Pract Res Clin Gastroenterol,16,663-678.
12. Day, CP,James, OF(1998).Steatohepatitis: a tale of two hits.Gastroenterology,114,842-845.
13. Eslami, L,Merat, S,Moghaddam, SN(2009).Treatment of nonalcoholic fatty liver disease (NAFLD): a systematic review.Middle East J Dig Dis,1,89-99.
14. Farrell, GC,George, J,Hall, P,McCullough, AJ(2005).Fatty Liver Disease: NASH and Related Disorders.Oxford, England:Blackwell.
15. Harrison, SA,Kadakia, S,Lang, KA,Schenker, S(2002).Nonalcoholic steatohepatitis: what we know in the new millennium.Am J Gastroenterol,97,2714.
16. Hong, XZ,Li, LD,Wu, LM(2007).Effects of finofibrate and xuezhikang on high-fat dietinduced non-alcoholic fatty liver disease.Clin Exp Pharmacol Physiol,34,27-35.
17. Huseini, HF,Alavian, SM,Heshmat, R,Heydari, MR,Abolmaali, K(2005).The efficacy of Liv-52 on liver cirrhotic patients: a randomized, double-blind, placebo-controlled first approach.Phytomedicine,12,619-624.
18. Kalab, M,Krechler, T(1997).Effect of the hepatoprotective drug Liv.52 on liver damage.J Czech Physicians,24,758-760.
19. Lima, VM,Oliveira, CP,Sawada, LY(2007).Yo jyo hen shi ko, a novel Chinese herbal prevents nonalcoholic steatohepatitis in ob/ob mice fed a high fat or methionine-choline-deficient diet.Liver Int,27,227.
20. Malnick, SDH,Beergabel, M,Knobler, H(2003).Nonalcoholic fatty liver: a common manifestation of a metabolic disorder.QJM,96,699-709.
21. Ministry of Health and Family Welfare. Department of Ayurveda, Yoga, Naturopathy, Unani, Siddha and Homeopathy(2007).The Ayurvedic Pharmacopoeia of India Government of Indiavol. 2.New Delhi, India:Ministry of Health and Family Welfare.
22. Mlinar, B,Marc, J,Janez, PM,Pfeifer, M(2007).Molecular mechanisms of insulin resistance and associated diseases.Clin Chim Acta,375,20-35.
23. Nanji, AA(2004).Another animal model for nonalcoholic steatohepatitis: how close to the human condition?.Am J Clin Nutr,79,350-351.
24. Oneta, CM,Dufour, JF(2002).Nonalcoholic fatty liver disease: treatment options based on pathogenic considerations.Swiss Med Wkly,132,493-505.
25. Ota, T,Takamura, T,Kurita, S(2007).Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.Gastroenterology,132,282-293.
26. Pinto, HC,Moura, DEMC,Day, CP(2006).Nonalcoholic steatohepatitis: from cell biology to clinical practice.J Hepatol,44,197-208.
27. Rivera, CA(2008).Risk factors and mechanisms of nonalcoholic steatohepatitis.Pathophysiology,15,109.
28. Svegliati-Baroni, G,Candelaresi, C,Saccomanno, S(2006).A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-and n-3 polyunsaturated fatty acid treatment on liver injury.Am J Cardiovasc Pathol,169,846-860.
29. Tiwari, AK(2004).Antioxidants: new-generation therapeutic base for treatment of polygenic disorders.Curr Sci.,86,1092-1102.
30. Vidyashankar, S,Mitra, SK,Nandakumar, KS(2010).Liv.52 protects HepG2 cells from oxidative damage induced by tert-butyl hydroperoxide.Mol Cell Biochem,333,41-48.
31. Vidyashankar, S,Patki, PS(2010).Liv.52 attenuate copper induced toxicity by inhibiting glutathione depletion and increased antioxidant enzyme activity in HepG2 cells.Food Chem Toxicol,48,1863-1868.
32. Vitaglione, P,Morisco, F,Caporaso, N,Fogliano, V(2004).Dietary antioxidant compounds and liver health.Crit Rev Food Sci Nutr,44,575-586.
33. Willcox, JK,Ash, SL,Catignani, GL(2004).Antioxidants and prevention of chronic disease.Crit Rev Food Sci Nutr,44,275-295.
34. World Health Organization(2000).General Guidelines for Methodologies Research and Evaluation of Traditional Medicine.Geneva, Switzerland:World Health Organization.
35. Xu, P,Zhang, XG,Li, YM,Yu, CH,Xu, L,Xu, GY(2006).Research on the protection effect of pioglitazone for nonalcoholic fatty liver disease (NAFLD) in rats.J Zhejiang Univ Sci.,7,627-633.
36. Yalniz, M,Bahcecioglu, IH,Kuzu, N(2007).Preventive role of genistein in an experimental nonalcoholic steatohepatitis model.J Gastroenterol Hepatol,22,2009-2014.

1. Mohammadreza Doostabadi,Mohammad Hassanpour-Fard,Moammadmehdi Hassanzadeh-Taheri,Mehran Hosseini,Khadijeh Vazifeshenas-Darmiyan,Hesam Moodi(2018).Co-administration effects of aqueous extract of turnip leaf and metformin in diabetic rats.Journal of Traditional and Complementary Medicine,8(1),178-183.